Clinicians at Dana-Farber/Brigham and Women’s Cancer Center already use targeted therapies that pinpoint genetic mutations in a select number of cancers, including colon, lung, breast, and some leukemias and sarcomas.
The Profile program aims to identify a far greater number of mutations for a wider array of cancers, ultimately enabling clinicians to treat more cancers with targeted therapies in the future.
Related Articles on Brigham and Women’s Hospital:
Brigham and Women’s Offers Paid High School Internships to Boost Interest in Healthcare
Dr. Karen Joynt of Brigham and Women’s in Boston to Discuss Readmissions
Brigham and Women’s Hospital CIO Sue Schade: Top Health IT Priorities
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
